Cargando…
Galectin-3 inhibition as a potential therapeutic target in non-alcoholic steatohepatitis liver fibrosis
Nonalcoholic fatty liver disease continues to be one of the major health challenges facing the world, with estimates of non-alcoholic steatohepatitis (NASH) prevalence in over 25 percent of the world’s population. NASH represents a spectrum of disease that may lead to hepatic fibrosis and eventual c...
Autor principal: | Kram, Michael |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Baishideng Publishing Group Inc
2023
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10011901/ https://www.ncbi.nlm.nih.gov/pubmed/36926236 http://dx.doi.org/10.4254/wjh.v15.i2.201 |
Ejemplares similares
-
Is vitamin D receptor a druggable target for non-alcoholic steatohepatitis?
por: Cao, Ying, et al.
Publicado: (2020) -
Mechanisms of ductular reaction in non-alcoholic steatohepatitis
por: Chen, Yue, et al.
Publicado: (2022) -
Galectin-3 and IL-33/ST2 axis roles and interplay in diet-induced steatohepatitis
por: Pejnovic, Nada, et al.
Publicado: (2016) -
Th17 involvement in nonalcoholic fatty liver disease progression to non-alcoholic steatohepatitis
por: Chackelevicius, Carla Melisa, et al.
Publicado: (2016) -
Fibroblast growth factor signaling in non-alcoholic fatty liver disease and non-alcoholic steatohepatitis: Paving the way to hepatocellular carcinoma
por: Ocker, Matthias
Publicado: (2020)